Location:2012 Annual Report
1a. Objectives (from AD-416):
1. To develop reagents for the sensitive detection of BoNTs in ELISA or ALISSA assay formats. 2. To optimize techniques for the recovery and detection of toxin in animal tissues and sera. 3. To determine the pharmacokinetics of botulinum neurotoxins in oral and parenteral mouse models of intoxication.
1b. Approach (from AD-416):
Monoclonal antibodies directed against botulinum neurotoxins (BoNTs) serotypes B, E and F will be produced and used in sensitive in vitro assays to detect toxin in animal sera and tissues. Animals will be intoxicated and the half life and tissue distribution of the toxins determined.
3. Progress Report:
In FY12 the research included collaborative development of assay technologies for detection of botulinum neurotoxins (BoNTs) in food and sera. Monoclonal antibodies against BoNT serotypes A and B were optimized for the detection of toxin in sera using a multiwell plate-based electrochemiluminescence (ECL) assay system. Pharmacokinetics of BoNTs and therapeutic antibody-bound BoNTs were studied in sera using the ECL assay system. Collaborators provided humanized therapeutic antibodies for testing of toxin neutralization and expertise in new assay technology for the detection and visualization of toxin in neurons and in liver. Research progress report, addresses objectives 1 and 2 of the parent project.